Quantbot Technologies LP purchased a new stake in Balchem Co. (NASDAQ:BCPC - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 5,342 shares of the basic materials company's stock, valued at approximately $871,000.
A number of other hedge funds also recently made changes to their positions in the stock. Westside Investment Management Inc. acquired a new position in Balchem in the third quarter valued at $27,000. R Squared Ltd acquired a new position in shares of Balchem in the 4th quarter valued at about $29,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Balchem during the 3rd quarter valued at about $35,000. Venturi Wealth Management LLC acquired a new stake in Balchem during the fourth quarter worth approximately $95,000. Finally, Smartleaf Asset Management LLC increased its holdings in Balchem by 230.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 645 shares of the basic materials company's stock worth $106,000 after purchasing an additional 450 shares in the last quarter. 87.91% of the stock is currently owned by institutional investors.
Balchem Stock Down 1.4 %
NASDAQ:BCPC traded down $2.32 on Friday, hitting $163.79. The stock had a trading volume of 151,524 shares, compared to its average volume of 122,072. The company has a quick ratio of 1.16, a current ratio of 1.99 and a debt-to-equity ratio of 0.19. Balchem Co. has a 52 week low of $137.69 and a 52 week high of $186.03. The business's fifty day moving average is $165.26 and its 200 day moving average is $169.28. The company has a market cap of $5.33 billion, a PE ratio of 41.68, a P/E/G ratio of 4.41 and a beta of 0.63.
Balchem (NASDAQ:BCPC - Get Free Report) last issued its earnings results on Friday, February 21st. The basic materials company reported $1.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.11 by ($0.08). The firm had revenue of $240.00 million during the quarter, compared to the consensus estimate of $239.96 million. Balchem had a return on equity of 11.37% and a net margin of 13.47%. On average, equities research analysts expect that Balchem Co. will post 4.64 EPS for the current fiscal year.
Analysts Set New Price Targets
BCPC has been the topic of a number of research analyst reports. Sidoti upgraded Balchem to a "hold" rating in a report on Tuesday, February 25th. StockNews.com lowered shares of Balchem from a "buy" rating to a "hold" rating in a research note on Tuesday, February 25th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $190.00 price target on shares of Balchem in a research note on Monday, February 24th.
Get Our Latest Report on Balchem
About Balchem
(
Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Read More
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
